This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Litigation Settlements, Data Compliance Reviews, And Clinical Trials Pave Way For Solid Footing In Healthcare - Research Report On Pfizer, Merck, Bristol-Myers Squibb, Keryx And Pacira Pharmaceuticals

NEW YORK, June 17, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: BMY), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), and Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On June 12, 2013, Pfizer Inc. (Pfizer) announced that it has reached a $2.15 billion settlement with Teva Pharmaceuticals and Sun Pharmaceuticals for patent-infringement damages related to the launches of the generic Protonix in the US. Amy W. Schulman, Executive Vice President and General Counsel of Pfizer, said, "We are pleased with today's settlement, which recognizes the validity and value of the innovation that led to Protonix." Schulman added, "Protecting intellectual property is vital as we develop new medicines that save and enhance patients' lives." Pfizer will receive 64% of the compensation, and the remaining will be given to Nycomed, which is now part of Takeda. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


Merck & Co. Inc. Research Report

On June 12, 2013, Merck & Co. Inc. (Merck) commented on the NIDDK-NCI Workshop and the American Diabetes Association's (ADA) call for an independent review of data about the safety of incretin-based diabetes medicines, including GLP-1 analogs and DPP-4 inhibitors, such as Januvia (sitagliptin). Michael Rosenblatt, M.D., Chief Medical Officer of Merck, stated, "Nothing is more important to Merck than the safety of our medicines and the people who take them. We welcome opportunities to discuss the data that support the safety profile of sitagliptin in the treatment of adults with type 2 diabetes. Type 2 diabetes is a disease with serious consequences if left untreated." Rosenblatt continued, "We are committed to participating in an independent review of our data, and will join the ADA in planning for such an initiative." The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,817.43 +97.51 0.55%
S&P 500 2,092.92 +12.51 0.60%
NASDAQ 5,133.4340 +24.7680 0.48%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs